The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Open accessAbstract
Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in Alzheimer's disease (AD) because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AchE for myasthenia gravis had effectively proven that AchE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEI) continue to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs in development and their respective mechanisms of actions. This pharmacological approach continues to be active with many promising compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Tacrine Derivatives and Alzheimers Disease
Tumiatti, V., Minarini, A., Bolognesi, M. L., Milelli, A., Rosini, M., & Melchiorre, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111206 · Cited by 225 · cited 2×
“Eventually, tacrine was discontinued due to the aforementioned liver toxicity which was thought to be caused by the affinity for BuChE [2] and because less toxic, better tolerated drugs with easier dosing schedule were approved.”
BackgroundCamps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badia, A., Clos, M. V., Camins, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8001313 · Cited by 205
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Wang, B.-S., Wang, H., Wei, Z.-H., Song, Y., Zhang, L., & Chen, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0189-x · Cited by 148
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Self-citationZheng, H., Youdim, M. B. H., & Fridkin, M. (2010) · ACS Chemical Biology · doi:10.1021/cb900264w · Cited by 106
Guo, A. J. Y., Xie, H. Q., Choi, R. C. Y., Zheng, Y., Bi, C. W. C., Xu, S. L., Dong, T. T.-X., & Tsim, K. W. K. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.05.002 · Cited by 104
Targeting Alzheimer’s disease: Novel indanone hybrids bearing a pharmacophoric fragment of AP2238
Rizzo, S., Bartolini, M., Ceccarini, L., Piazzi, L., Gobbi, S., Cavalli, A., Recanatini, M., Andrisano, V., & Rampa, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.071 · Cited by 99
Orhan, G., Orhan, I., Subutay-Oztekin, N., Ak, F., & Sener, B. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909787002582 · Cited by 90
Metrifonate for Alzheimer's disease
López-Arrieta, J., & Schneider, L. S. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003155.pub3 · Cited by 76
Donepezil: potential neuroprotective and disease-modifying effects
Jacobson, S. A., & Sabbagh, M. N. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1363 · Cited by 72
Self-citationKorábečný, J., Musílek, K., Holas, O., Binder, J., Zemek, F., Marek, J., Pohanka, M., Opletalová, V., Dohnal, V., & Kuča, K. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.08.044 · Cited by 67
Samadi, A., Marco, J. L., Soriano, E., Álvarez-Pérez, M., Chioua, M., Romero, A., González‐Lafuente, L., Gandía, L., Roda, J. M., López, M. G., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.095 · Cited by 59
Development of huperzine A and B for treatment of Alzheimer's disease
Bai, D. (2007) · Pure and Applied Chemistry · doi:10.1351/pac200779040469 · Cited by 59
A novel anti-Alzheimer's disease drug, ladostigil
Weinreb, O., Amit, T., Bar‐Am, O., & Youdim, M. B. H. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-386467-3.00010-8 · Cited by 54
Jung, H. A., Jung, Y. J., Hyun, S. K., Min, B.-S., Kim, D., Jung, J. H., & Choi, J. S. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.267 · Cited by 54
New potential AChE inhibitor candidates
de Paula, A. A. N., Martins, J. B. L., dos Santos, M. L., Nascente, L. D. C., Romeiro, L. A. S., Areas, T. F. M. A., Vieira, K. S. T., Gambôa, N. F., Castro, N. G., & Gargano, R. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.03.045 · Cited by 52
Acetylcholinesterase Inhibitory Activity of Uleine from Himatanthus lancifolius
Seidl, C., Correia, B. L., Stinghen, A. E. M., & Santos, C. A. D. M. (2010) · Zeitschrift für Naturforschung C · doi:10.1515/znc-2010-7-804 · Cited by 43
Synthesis of physostigmine analogues and evaluation of their anticholinesterase activities
Zhan, Z., Bian, H.-L., Wang, J., & Shan, W. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.097 · Cited by 38
Ladostigil prevents age-related glial activation and spatial memory deficits in rats
Weinstock, M., Luques, L., Poltyrev, T., Bejar, C., & Shoham, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.06.004 · Cited by 37
Ali, M. A., Yar, M. S., Hasan, M. Z., Ahsan, M. J., & Pandian, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.042 · Cited by 33
Lehr, T., Staab, A., Tillmann, C., Trommeshauser, D., Raschig, A., Schaefer, H. G., & Kloft, C. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02855.x · Cited by 23
Shi, Y., Zhang, H., Wang, W., Fu, Y., Xia, Y., Tang, X.-C., Bai, D., & He, X. (2009) · Acta Pharmacologica Sinica · doi:10.1038/aps.2009.91 · Cited by 21
Cited by
Redox- and non-redox-metal-induced formation of free radicals and their role in human disease
Valko, M., Jomova, K., Rhodes, C. J., Kuča, K., & Musílek, K. (2016) · Archives of Toxicology · doi:10.1007/s00204-015-1579-5 · Cited by 1,022
Cholinesterase inhibitors as Alzheimer's therapeutics (Review)
Sharma, K. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10374 · Cited by 602
Santos, T. C. D., Gomes, T. M., Pinto, B. A. S., Camara, A. L., & Paes, A. M. D. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01192 · Cited by 389
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca-Santos, B., Chorilli, M., & Palmira Daflon Gremião, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 308
Metadata
- Authors
- Mehta, M., Adem, A., & Sabbagh, M.
- Venue
- International Journal of Alzheimer's Disease
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 2090-0252 (ISSN-L)
- 2090-8024
- OpenAlex
- W2017645489
- Cited by
- 436
- References
- 30
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.